Biliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors
Journal of clinical medicine · 2026 Oct 16 · Ghusn W, Abi-Aad SJ, Hurtado MD et
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 15 20:00 ETSource: Journal of clinical medicine
From the source
Read at pubmed.ncbi.nlm.nih.govBiliary and Pancreatic Safety of Incretin-Based Therapies in Obesity and Type 2 Diabetes: A Propensity-Matched Real-World Comparison of Tirzepatide, Semaglutide, and DPP-4 Inhibitors
Journal of clinical medicine · 2026 Oct 16 · Ghusn W, Abi-Aad SJ, Hurtado MD et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42941539/
